Chronic lithium downregulates cyclooxygenase-2 activity and prostaglandin E2 concentration in rat brain

Molecular Psychiatry

Volumn 7, Issue 8, 2002, Pages 845-850

  Bosetti, F ^a   Rintala, J ^a   Seemann, R ^a   Rosenberger, T A ^a   Contreras, M A ^a   Rapoport, S I ^a   Chang, M C ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Arachidonic acid; Bipolar disorder; Brain; Chronic; Cyclooxygenase; Lithium; Phospholipase A2; Prostaglandin; Rat

Indexed keywords

ARACHIDONIC ACID; BRAIN PROTEIN; CALCIUM ION; CYCLOOXYGENASE 2; LITHIUM CHLORIDE; MESSENGER RNA; PHOSPHOLIPASE A2; PHOSPHOLIPID; PROSTAGLANDIN E2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARACHIDONIC ACID METABOLISM; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME MECHANISM; MANIC DEPRESSIVE PSYCHOSIS; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIMANIC AGENTS; ARACHIDONIC ACID; BRAIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DINOPROSTONE; DOWN-REGULATION; ENZYME ACTIVATION; ISOENZYMES; LITHIUM CHLORIDE; MALE; MEMBRANE PROTEINS; PHOSPHOLIPASES A; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; RATS, INBRED F344;

EID: 0036385734     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4001111     Document Type: Article

References (52)

1. Cade JFJ. Lithium salts in the treatment of psychotic excitement. Med J Austral 1949; 36: 349-352.
2. Manji HK, Potter WZ, Lenox RH. Signal transduction pathways. Molecular targets for lithium's action. Arch Gen Psychiatry 1995; 52: 531-543.
3. Jope RS. Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry 1999; 4: 117-128.
4. Phiel CJ, Klein PS. Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 2001; 41: 789-813.
5. Chen RW, Chuang DM. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J Biol Chem 1999; 274: 6039-6042.
6. 2 and arachidonic acid release in signal transduction. Biochem Soc Trans 1990; 18: 503-507.
7. 2 in activated mast cells. J Biol Chem 1997; 272: 3231-3237.
8. Fitzpatrick FA, Soberman R. Regulated formation of eicosanoids. J Clin Invest 2001; 107: 1347-1351.
9. 1 in the affective disorders and in alcoholism. Br Med J 1980; 280: 1363-1366.
10. Karmazyn M, Manku MS, Horrobin DF. Changes of vascular reactivity induced by low vasopressin concentrations: interactions with cortisol and lithium and possible involvement of prostaglandins. Endocrinology 1978; 102: 1230-1236.
11. Farooqui AA, Horrocks LA, Farooqui T. Glycerophospholipids in brain: their metabolism, incorporation into membranes, functions, and involvement in neurological disorders. Chem Phys Lipids 2000; 106: 1-29.
12. Brash AR. Arachidonic acid as a bioactive molecule. J Clin Invest 2001; 107: 1339-1345.
13. Wolfe LS, Horrocks LA. Eicosanoids. In: Siegel GJ, Agranoff BW, Albers RW, Molinoff PB (eds). Basic Neurochemistry, 5th edn. Raven Press: New York, 1994, pp 475-490.
14. Chang MC, Grange E, Rabin O, Bell JM, Rapoport SI. Lithium decreases turnover of arachidonate in several phospholipids. Neurosci Lett 1996; 220: 171-174.
15. Chang MC, Bell JM, Purdon AD, Chikhale EG, Grange E. Dynamics of docosahexaenoic acid metabolism in the central nervous system: lack of effect of chronic lithium treatment. Neurochem Res 1999; 24: 399-406.
16. 2 activity. Neurochem Res 1998; 23: 887-892.
17. 2 is a target for chronic lithium in rat brain. Neuroreport 1999; 10: 3887-3890.
18. Herschman HR. Prostaglandin synthase 2. Biochim Biophys Acta 1996; 1299: 125-140.
19. Smith WL, Garavito DL, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996; 271: 33157-33160.
20. Kaufmann WE, Worley PF, Pegg J, Bremer M, Isakson P. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci USA 1996; 93: 2317-2321.
21. Niwa K, Araki E, Morham SG, Ross ME, Iadecola C. Cyclooxygenase-2 contributes to functional hyperemia in whisker-barrel cortex. J Neurosci 2000; 20: 763-770.
22. Yamamoto T, Nozaki-Taguchi N. Analysis of the effects of cyclooxygenase (COX)-1 and COX-2 in spinal nociceptive transmission using indomethacin, a non-selective COX inhibitor, and NS-398, a COX-2 selective inhibitor. Brain Res 1996; 739: 104-110.
23. Frank E, Swartz HA, Kupfer DJ. Interpersonal and social rhythm therapy: managing the chaos of bipolar disorder. Biol Psychiatry 2000; 48: 430-432.
24. Martinez FE, Harabor A, Amankwah EK, Hart DA, Belik J. Urethane suppresses rat lung inducible cyclooxygenase and nitric oxide synthase mRNA levels. Inflamm Res 2000; 49: 727-731.
25. Feng L, Xia Y, Garcia GE, Hwang D, Wilson CB. Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor necrosis factor-alpha, and lipopolysaccharide. J Clin Invest 1995; 95: 1669-1675.
26. Powell WS. Reversed-phase high-pressure liquid chromatography of arachidonic acid metabolites formed by cyclooxygenase and lipoxygenases. Anal Biochem 1985; 148: 59-69.
27. Taniguchi Y, Yokoyama K, Inui K, Deguchi Y, Furukawa K, Noda K. Inhibition of brain cyclooxygenase-2 activity and the antipyretic action of nimesulide. Eur J Pharmacol 1997; 330: 221-229.
28. Bosetti F, Seemann R, Bell JM, Zahorchak R, Friedman E, Rapoport SI et al. Analysis of gene expression with cDNA microarrays in rat brain after 7 and 42 days of oral lithium administration. Brain Res Bull 2002; 57: 205-209.
29. Furth EE, Hurtubise V, Schott MA, Laposata M. The effect of endogenous essential and nonessential fatty acids on the uptake and subsequent agonist-induced release of arachidonate. J Biol Chem 1989; 264: 18494-18501.
30. Morita L, Schindler M, Regier MK, Otto JC, Hori T, DeWitt DL et al. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J Biol Chem 1995; 270: 10902-10908.
31. 2 gene in human and rat: chromosomal localization and polymorphic markers. Genomics 1995; 26: 138-141.
32. Chang MC, Contreras MA, Rosenberger TA, Rintala JJ, Bell JM, Rapoport SI. Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: a possible common effect of mood stabilizers. J Neurochem 2001; 77: 796-803.
33. Szupera Z, Mezei Z, Kis B, Gecse A, Vecsei L, Telegdy G. The effects of valproate on the arachidonic acid metabolism of rat brain microvessels and of platelets. Eur J Pharmacol 2000; 387: 205-210.
34. Verburg KM, Maziasz TJ, Weiner E, Loose L, Geis GS, Isakson PC. COX-2 specific inhibitors: definition of a new therapeutic concept. Am J Ther 2001; 8: 49-64.
35. Ketterer MW, Brymer J, Rhoads K, Kraft P, Lovallo WR. Is aspirin, as used for antithrombosis, an emotion-modulating agent? J Psychosom Res 1996; 40: 53-58.
36. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991; 266: 12866-12872.
37. Dixon DA, Kaplan CD, McIntyre TM, Zimmerman GA, Prescott SM. Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3′ untranslated region. J Biol Chem 2000; 275: 11750-11757.
38. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 1992; 89: 7384-7388.
39. 2 regulates the level and stability of cyclooxygenase-2 mRNA through activation of p38 mitogen activated protein kinase in interleukin-1β-treated human synovial fibroblasts. J Biol Chem 2001; 34: 31720-31731.
40. Horrobin DF, Mtabaji JP, Manku MS, Karmazyn M. Lithium as a regulator of hormone-stimulated prostaglandin synthesis. In: Johnson FN, Johnson S (eds). Lithium in Medical Practice. University Park Press: Baltimore MD, 1978, pp 243-246.
41. 2 gene and bipolar affective disorder. Psychiatr Genet 1995; 5: 177-180.
42. Jacobsen NJ, Franks EK, Owen MJ, Craddock NJ. Mutational analysis of phospholipase A2A: a positional candidate susceptibility gene for bipolar disorder. Mol Psychiatry 1999; 4: 274-279.
43. Hayaishi O. Prostaglandin D2 and sleep - a molecular genetic approach. J Sleep Res 1999; 8: 60-64.
44. Yoshida Y, Matsumura H, Nakajima T, Mandai M, Urakami T, Kuroda K et al. Prostaglandin E (EP) receptor subtypes and sleep: promotion by EP4 and inhibition by EP1/EP2. Neuroreport 2000; 11: 2127-2131.
45. Hayaishi O. Molecular mechanisms of sleep-wake regulation: a role of prostaglandin D2. Philos Trans R Soc Lond B Biol Sci 2000; 355: 275-280.
46. Matsumura H, Honda K, Choi WS, Inoue S, Sakai T, Hayaishi O. Evidence that brain prostaglandin E2 is involved in physiological sleep-wake regulation in rats. Proc Natl Acad Sci USA 1989; 86: 5666-5669.
47. Horrobin DF, Lieb J. A biochemical basis for the actions of lithium on behaviour and on immunity: relapsing and remitting disorders of inflammation and immunity such as multiple sclerosis or recurrent herpes as manic-depression of the immune system. Med Hypotheses 1981; 7: 891-905.
48. Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999; 56: 407-412.
49. Noaghiul S, Hibbeln JR, Weissman MM. Cross-national comparisons of seafood consumption and rates of bipolar disorder. Am J Psychiatry (in press).
50. Corey EJ, Shih C, Cashman JR. Docosahexaenoic acid is a strong inhibitor of prostaglandin but not leukotriene biosynthesis. Proc Natl Acad Sci USA 1983; 80: 3581-3584.
51. Rubin D, Laposata M. Cellular interactions between n-6 and n-3 fatty acids: a mass analysis of fatty acid elongation/desaturation, distribution among complex lipids, and conversion to eicosanoids. J Lipid Res 1992; 33: 1431-1440.
52. Seung Kim HF, Weeber EJ, Sweatt JD, Stoll AL, Marengell LB. Inhibitory effects of omega-3 fatty acids on protein kinase C activity in vitro. Mol Psychiatry 2001; 6: 246-248.